multimmune GmbH

..........delivering innovative cancer theranostics

With current statistics indicating that the lifetime risk of developing cancer is now 1 in 2, it is essential that approaches for diagnosing and treating cancer continue to be improved.

Although progress in the development of new cancer therapies for the majority of tumour entities progresses at a pace, key challenges in the management and treatment of aggressive disease remain. Another big challenge relates to the time and cost of drug development, and thereby the ability of the healthcare providers to afford the therapeutics that are developed. The identification of more ‘universal’ targeting structures that are present across different cancer entities will consolidate the costs of developing therapies during the pre-clinical and early clinical phases.


VISION & MISSION

To reduce cancer deaths and improve the lives of cancer patients by developing revolutionary products which specifically target primary tumors and aggressive, metastatic disease. 


Creating value:

  • product and technology platform based on a widely, but selectively expressed tumor-specific marker;
  • pipeline of therapeutic, delivery, diagnostic and imaging platforms.

 

Commercialization:

  • out-licensing technology to the commercial sector;
  • development and delivery of selected co-development partnerships for complementary technologies.